Why Biogen (BIIB) is Poised to Beat Earnings Estimates Again
Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
BIIB - Biogen Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$217.11
DETAILS
HIGH:
$260.00
LOW:
$157.00
MEDIAN:
$223.50
CONSENSUS:
$217.11
UPSIDE:
9.02%
Stock News
Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.
Biogen struggled in recent years after a major blockbuster lost exclusivity. The company's new focus on growth is bearing fruit -- and the latest acquisition strengthens Biogen's position in the key area of immunology.
Amgen or Biogen: Which Biotech Stock Appears Better Poised?
AMGN stands out compared to Biogen given its broader product portfolio, pipeline depth and steadier growth outlook despite patent and competition risks.
New Strong Sell Stocks for June 30th
BBIB, BGSI and CLCGY have been added to the Zacks Rank #5 (Strong Sell) List on June 30, 2026.
Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs
LLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, approvals and deal activity adding momentum.
Biogen (BIIB) Moves 7.0% Higher: Will This Strength Last?
Biogen (BIIB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Block & Leviton LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Biogen, Inc. – BIIB
BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Block & Leviton LLP announces that the United States District Court for the District of Massachusetts has approved the following announcement of a proposed class action settlement that would benefit purchasers of common stock of Biogen, Inc. (NASDAQ: BIIB): OKLAHOMA FIREFIGHTERS PENSION AND RETIREMENT SYSTEM, Plaintiff, v. BIOGEN INC.
Biogen to Highlight Breadth of Alzheimer's Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen
CAMBRIDGE, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced it will present new data across its Alzheimer's disease portfolio at the Alzheimer's Association International Conference (AAIC) 2026, taking place July 12-15 in London, UK. Presentations will include data from the Phase 2 CELIA study evaluating diranersen, an investigational tau-targeting antisense oligonucleotide (ASO), and new analyses from studies of LEQEMBI® (lecanemab).
Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout
Biogen said on Friday it had either paused or discontinued funding for most of Apellis Pharmaceuticals' research programs as it integrates the rare-disease drugs specialist it purchased for $5.6 billion earlier this year.
Can Biogen's New Drugs Revive Growth Amid Legacy Sales Slump?
Biogen is betting on Leqembi, Skyclarys and Zurzuvae to offset declining legacy drug sales, but replacing lost revenues may take time.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Biogen To Acquire RayThera For Up To $1 Billion, Expanding Immunology Pipeline
Biogen acquires RayThera in a deal worth up to $1 billion, adding early-stage immunology assets as it expands beyond Alzheimer's disease.
Biogen to Strengthen Immunology Pipeline With $1B RayThera Buyout
BIIB is set to acquire RayThera for up to $1 billion, adding anti-inflammatory candidates that could expand its immunology pipeline and future growth.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
NEW YORK, June 18, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Biogen to acquire RayThera for $1 billion
Biogen said on Wednesday it would acquire drug discovery company RayThera for $1 billion, including milestone payments.
Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
Acquisition adds multiple immunology assets to Biogen's portfolio, including a lead asset poised to enter Phase 1 development Acquisition adds multiple immunology assets to Biogen's portfolio, including a lead asset poised to enter Phase 1 development
The Healthcare M&A Wave
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES, June 11, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or "the Company") (NASDAQ: BIIB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Price Targets
Biogen price target lowered to $222 from $224 at Morgan Stanley
$222.00
(was $205.70)
Terence Flynn
·
Morgan Stanley
Biogen price target raised to $242 from $227 at RBC Capital
$242.00
(was $208.46)
RBC Capital
Biogen price target raised to $157 from $150 at HSBC
$157.00
(was $213.26)
Morten Herholdt
·
HSBC
Biogen price target raised to $224 from $206 at Morgan Stanley
$224.00
(was $198.67)
Morgan Stanley
Biogen price target lowered to $221 from $236 at Mizuho
$221.00
(was $200.05)
Salim Syed
·
Mizuho Securities
Biogen upgraded to Buy from Hold at Needham
$255.00
(was $195.34)
Needham
Biogen (BIIB) PT Raised to $227 at RBC Capital
$227.00
(was $193.08)
Brian Abrahams
·
RBC Capital
Biogen price target raised to $225 from $214 at Piper Sandler
$225.00
(was $191.37)
Piper Sandler
Biogen price target raised to $206 from $200 at Morgan Stanley
$206.00
(was $188.76)
Morgan Stanley
Biogen price target raised to $222 from $213 at RBC Capital
$222.00
(was $190.78)
Brian Abrahams
·
RBC Capital
Biogen price target raised to $196 from $191 at Wedbush
$196.00
(was $194.38)
Wedbush
Biogen price target raised to $260 from $246 at Guggenheim
$260.00
(was $194.38)
Guggenheim
Biogen upgraded to Overweight from Equal Weight at Wells Fargo
$250.00
(was $177.35)
Mohit Bansal
·
Wells Fargo
Biogen upgraded to Overweight from Neutral at Piper Sandler
$214.00
(was $176.37)
Piper Sandler
Biogen price target raised to $200 from $190 at Morgan Stanley
$200.00
(was $173.48)
Morgan Stanley
Biogen initiated with an Equal Weight at Barclays
$185.00
(was $192.08)
Emily Field
·
Barclays
Biogen price target raised to $236 from $207 at Mizuho
$236.00
(was $188.99)
Mizuho Securities
Biogen price target raised to $187 from $178 at Wedbush
$187.00
(was $192.72)
Laura Chico
·
Wedbush
Goldman Sachs Reiterates Buy Rating on Biogen (BIIB)
$231.00
(was $196.00)
Wolfe Research
Biogen price target raised to $233 from $217 at RBC Capital
$233.00
(was $195.93)
RBC Capital